PolyPid (PYPD) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

PolyPid Ltd. (PYPD) is developing the PLEX system for prolonged local antibiotic application, which promises high profitability and a steady cash flow. The company achieves cost optimization by outsourcing production and logistics to third-party contractors. The stock's price history reflects an EV/EBITDA of 0.00, while business success relies on a single core product and remains dependent on regulatory decisions.

PolyPid - PYPD Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/10/2026)

Summary analytical data breakdowns for polypid.com (PYPD)

- current price and projected stock value:

Stock Price PolyPid|PYPD - Analyst Median Target

- market capitalization details:

Market Value PYPD|PYPD - Business Value

- book value of equity indicators:

Book Value per Share PolyPid|PYPD - Net Asset Value|Market Capitalization to Book Value Ratio polypid.com|PYPD - Company Assets

- company total debt and liquidity indicators:

- financial results and valuation multiples details:

PYPD - Company Profit|Expected Profit PolyPid Ltd.|PYPD - Business Payback Period|Future Price to Earnings PolyPid|PYPD - Market Cap to Earnings and Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PYPD|PYPD - Profit before interest, taxes and amortization|Earnings per share for the last twelve months PolyPid|PYPD - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months polypid.com|PYPD - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year PolyPid Ltd.

General company analysis:PolyPid Limited PYPD

For PolyPid Ltd. (PYPD), which implements robotics for screening and processing clinical trial data, this indicator serves as a measure of business value relative to its operating profit before depreciation and amortization. By analyzing the EV/EBITDA multiple on the time chart, an investor assesses the total value of assets and debts minus cash, which helps determine the fundamental stability of PolyPid Ltd. (PYPD) amid the capital-intensive automation of laboratories.

Analysis of competing companies

EV/EBITDA Multiple SMMT (Summit Therapeutics Inc)|Total Company Value to Operating Income Before Depreciation Ratio Moderna Therapeutics (MRNA)|PCVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TARS (tarsusrx.com) - Enterprise Value to Operating Income Before Depreciation|CRMD: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio MCRB (Seres Therapeutics Inc.)|SPRO (Spero) - EV/EBITDA Multiple|Company Value to EBITDA Scynexis SCYX|EV/EBITDA Multiple ANTX|Enterprise Value to EBITDA Ratio ysbiopharm.com LSB|Iterum Therapeutics - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio PHGE (BiomX Inc)|BioPharma Bio - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio 60 Degrees Pharmaceuticals SXTP|Oragenics, Inc. (OGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA opgen.com (OPGN)